A Randomized Phase III of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Not Available

Principal Investigator(s):

Davis, Elizabeth

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

03-14-2025

Trial Type:

Treatment

Protocol ID:

VICC-NTSAR24139

National Clinical Trial ID:

NCT06422806

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available